10-Q: IN8bio Reports Q1 2026 Financials, Faces Going Concern Doubt

IN8bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, reporting a net loss of $5.1 million and highlighting substantial doubt about its ability to continue as a going concern.

Summary

• IN8bio, Inc. reported a net loss of $5.1 million for the three months ended March 31, 2026, compared to a net loss of $5.6 million for the same period in 2025.
• Total operating expenses decreased to $5.3 million from $5.7 million year-over-year.
• The company had $21.9 million in cash and cash equivalents as of March 31, 2026.
• Management has identified substantial doubt about the company's ability to continue as a going concern, as current cash is not anticipated to fund operations for at least 12 months.
• The company plans to raise additional capital through equity or debt offerings, ATM programs, and strategic collaborations to address liquidity needs.
• Research and development expenses decreased by $0.4 million to $2.6 million, primarily due to lower direct costs for the INB-400 program and facility charges.
• General and administrative expenses remained stable at $2.7 million.
• The company did not sell any shares under its ATM program during the quarter.
• As of March 31, 2026, $5.9 million remained available for sale under the ATM program.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the substantial doubt about the company's going concern status and the continued operational losses, despite some positive developments in R&D expenses.

Positives

• Decrease in net loss to $5.1 million from $5.6 million in the prior year period.
• Reduction in total operating expenses to $5.3 million from $5.7 million.
• Interest income increased to $0.2 million from $0.1 million.
• The company has $21.9 million in cash and cash equivalents as of March 31, 2026.
• The company has $5.9 million remaining available for sale under its ATM program as of May 4, 2026.

Negatives

• The company has substantial doubt about its ability to continue as a going concern.
• The company incurred a net loss of $5.1 million for the quarter.
• The company has an accumulated deficit of $146.2 million as of March 31, 2026.
• Cash on hand is not expected to fund operations for at least 12 months.
• The company suspended further enrollment in the INB-400 Phase 2 trial to conserve capital.
• The company is heavily reliant on future capital raises and strategic collaborations, with no assurance of success.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• The company requires substantial additional funding to finance operations through regulatory approval.
• Failure to raise additional capital could force the company to delay, reduce, or explore other strategic options for development programs, or terminate operations.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to product candidates.
• The company has incurred significant operating losses since inception and anticipates continued substantial losses.
• The company has a limited operating history and no products approved for commercial sale.
• The success of the company is dependent on the clinical development, regulatory approval, and commercialization of its gamma-delta T cell product candidates.
• Interim clinical trial data may change as more patient data becomes available and is subject to audit and verification.
• The novel approaches of the DeltEx product candidates present significant development, manufacturing, and commercialization challenges.
• The clinical and commercial utility of the DeltEx platform is uncertain and may never be realized.
• Clinical product candidate development is a lengthy, expensive, and uncertain process.
• The company may encounter difficulties in enrolling patients in clinical trials.
• The company may not be able to file IND applications or commence additional clinical trials on expected timelines.
• Public opinion and scrutiny of cell-based immunotherapy and genetic modification approaches could impact the company.
• The company faces significant competition from entities with greater experience and resources.
• Manufacturing processes are complex, and difficulties could delay or prevent the supply of product candidates.
• Reliance on third-party contractors for manufacturing carries risks.
• Damage or loss to storage freezers or facilities could cause delays.
• Dependence on a single third-party supplier for manufacturing devices and lentiviral vectors poses a risk.
• Incorrect administration of gamma-delta T cells by third-party healthcare professionals could harm the business.
• Breaching license agreements could lead to loss of development and commercialization rights.
• Failure to obtain and maintain patent protection could allow competitors to commercialize similar products.
• Loss of key management personnel could impede development and commercialization efforts.
• Non-compliance with data privacy and security obligations could lead to regulatory actions and litigation.
• Unstable market and economic conditions could adversely affect the business and ability to raise capital.
• The company's ability to use net operating losses may be subject to limitations.
• Potential product liability suits and other claims could require expensive litigation or substantial damages.
• Coverage and adequate reimbursement may not be available for product candidates.
• Healthcare legislative reform measures could negatively impact the business.
• The FDA's ability to review and approve new products may be hindered by various factors.
• Actual or perceived failures to comply with data privacy and security obligations could lead to adverse consequences.
• An active trading market for the common stock may not be sustained.
• The market price of the common stock is volatile and could fluctuate substantially.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult.
• The exclusive forum provisions in the certificate of incorporation may limit stockholders' ability to obtain a favorable judicial forum.
• If research analysts do not publish research or publish unfavorable research, the stock price and trading volume could decline.
• The company will incur increased costs as a result of operating as a public company.

Future Outlook

The company expects to incur additional losses in the future as it advances its product candidates through clinical trials, expands its product candidate portfolio, grows its clinical, regulatory and quality capabilities, and incurs costs associated with operating as a public company. Management plans to fund operations by prioritizing the pipeline, raising additional capital through equity/debt offerings (including ATM offerings), and identifying strategic collaborations or licensing arrangements.

Management Comments

• The company continues to maintain cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility.
• These cash preservation measures may impact the company's ability and the timing to execute its strategy, including its ability to achieve anticipated milestones and the timing of regulatory filings for its preclinical and clinical programs.
• To continue to fund the operations of the company beyond this time period, management has developed plans, which primarily consist of pipeline prioritization, raising additional capital through some combination of equity and/or debt offerings, including through ATM offerings and private placements of securities, and identifying strategic collaborations, licensing or other arrangements to support development of the company's product candidates.

Industry Context

StockSavvy.ai notes that IN8bio operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on novel cell therapies. The company's reliance on future funding and the inherent risks in clinical development are common challenges within the industry, particularly for early-stage biotechnology firms.

Legal Proceedings

• The Company is not currently party to any material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if additional capital is raised through equity offerings.
• The company's ability to continue operations is dependent on securing additional funding, which could impact all stakeholders if not achieved.
• If additional capital is not available, the company may have to delay, scale back, or discontinue research and development programs, impacting future growth prospects.

Next Steps

• Complete treatment of all patients in the INB-100 Phase 1 trial, with long-term follow-up results anticipated in late 2026.
• Provide further clinical updates for INB-200/400, including additional mOS data, at medical meetings in mid- and late- 2026.
• Evaluate potential funding sources and strategic opportunities to support continued development of the INB-400 program toward potential commercialization.
• Continue to maintain cash preservation measures.
• Raise additional capital through equity and/or debt offerings, including through the ATM program.
• Identify strategic collaborations, licensing, or other arrangements to support development of product candidates.

Key Dates

Recommendation

While the company is in a critical stage of development with promising technology, the substantial doubt about its going concern status and the need for significant future financing warrant a cautious approach. Investors should monitor upcoming clinical data and the company's ability to secure necessary funding before considering a more aggressive stance.

Keywords

IN8bio, 10-Q, SEC Filing, Biopharmaceutical, Clinical Stage, Gamma-delta T cell, Cancer, Autoimmune Diseases, INB-100, INB-200, INB-400, DeltEx Platform, T cell engager, Net Loss, Going Concern, Liquidity, Capital Raise, Research and Development, Clinical Trials